TG Therapeutics (NASDAQ:TGTX) Shareholders Have Earned a 36% CAGR Over the Last Five Years
10 Health Care Stocks With Whale Alerts In Today's Session
TG Therapeutics Inc (TGTX): Short Seller Sentiment Is Bearish
Are Robust Financials Driving The Recent Rally In TG Therapeutics, Inc.'s (NASDAQ:TGTX) Stock?
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $49
H.C. Wainwright analyst Edward White maintains $TG Therapeutics(TGTX.US)$ with a buy rating, and maintains the target price at $49.According to TipRanks data, the analyst has a success rate of 32.9%
Analysts' Top Healthcare Picks: TG Therapeutics (TGTX), Boston Scientific (BSX)
Evaluating TG Therapeutics: Insights From 4 Financial Analysts
HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $49 Price Target
TG Therapeutics Analyst Ratings
What's Going On With TG Therapeutics Stock Wednesday?
Sector Update: Health Care Stocks Steady Premarket Wednesday
TG Therapeutics Shares Are Trading Higher After the Company Announced It Updated Its Data Presentations to Include New Five-year Data From the ULTIMATE I & II Phase 3 Trials Evaluating Briumvi (Ublituximab-xiiy) at the 2024 European Committee for...
TG Therapeutics Reports 30-Minute BRIUMVI Infusions Well Tolerated in Relapsing Multiple Sclerosis Trial
TG Therapeutics Presented Updated Data From The ENHANCE Phase 3b Trial Evaluating BRIUMVI (Ublituximab-xiiy) In Patients With Relapsing Forms Of Multiple Sclerosis (RMS)
Express News | TG Therapeutics: Data Also Showed Patients Switching From Prior Anti-Cd20 Treatment Can Successfully Eliminate Initial Briumvi Infusion
Express News | TG Therapeutics: Infusion Related Reactions in Patients Receiving 30-Minute Briumvi Infusions Were All Mild and Resolved Completely
New Data for BRIUMVI (Ublituximab-xiiy) Demonstrate That 92% of Patients With Relapsing Multiple Sclerosis Were Free From Disability Progression After 5 Years of Treatment
High Growth Tech Stocks In The United States You Should Know
TG Therapeutics Shares Are Trading Higher After It Was Announced the Stock Will Join the S&P SmallCap 600.
What's Going On With ADMA Biologics Stock Monday?